Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Are you currently facing challenges in achieving stable and efficient gene integration for your therapeutic development? Our high-efficiency genomic integration service helps you overcome these hurdles through advanced site-specific integration technologies, ensuring reliable and predictable gene expression.
Precision and efficiency in genomic integration are critical to the success of gene treatments and advanced biotechnology applications. Traditional approaches frequently produce random integration, resulting in variable gene expression, insertional mutagenesis, and silencing effects. The invention of high-efficiency genomic integration solves these constraints by allowing for the targeted and regulated insertion of desired genes into specified loci of the host genome. The study emphasizes the need of precise gene delivery for treatment success. The development of new gene insertion treatments emphasizes the continued need for effective and safe genomic integration procedures. High-efficiency integration reduces off-target effects while increasing the therapeutic potential of gene treatments.
Fig.1 In vivo, ex vivo, and in situ gene therapy approaches.1
Creative Biolabs offers a cutting-edge genomic integration service, empowering global clients with a dependable and highly efficient solution for targeted gene insertion. This service fuels the creation of innovative therapeutics and sophisticated cell models. Our unique approach employs mammalian-derived genome engineering enzymes to flawlessly introduce DNA of any size into precisely defined genomic locations, enabling the activation, deactivation, or modulation of specific gene functions. This capability is instrumental in applications such as building intricate disease models with precise genetic alterations or engineering cell lines to produce therapeutic proteins with superior characteristics.
Notably, our seamless integration mechanism operates without inducing double-stranded DNA breaks, a common drawback of some gene editing technologies. Furthermore, it bypasses the reliance on host DNA repair pathways or homologous recombination, which can introduce unwanted variability and errors. By circumventing these processes, our method significantly enhances efficiency and reliability, resulting in more consistent and predictable outcomes for integration into the recipient genome.
We design and construct a customized vector containing your gene of interest and the necessary components for site-specific integration. This includes the selection of an appropriate integration system and optimization of targeting sequences.
We optimize the chosen integration system to ensure high efficiency and specificity in your target cells. This may involve codon optimization of the gene of interest and fine-tuning the expression levels of the integration machinery.
We employ advanced transfection or transduction methods to deliver the integration vector into your target cells. The method is selected based on the cell type and the desired level of integration efficiency.
Following integration, we perform selection and screening to identify cells with successful and targeted gene insertion. This may involve antibiotic selection, PCR screening, or other molecular techniques.
We rigorously characterize the integrated cell lines to confirm the site of integration, copy number, and stability of gene expression. This includes Southern blotting, qPCR, and functional assays.
We provide you with the characterized stable cell lines or a comprehensive report detailing the integration process and results, including sequence-verified integration sites and expression data.
Partner with Creative Biolabs to achieve precise, stable, and high-efficiency genomic integration for your next-generation cell therapy or research program.
Discover How We Can Help - Request a Consultation
Virus-Based Transfection utilizes high-efficiency viral vectors such as lentivirus, retrovirus, and adenovirus to achieve stable, high-expression gene delivery, ensuring reliable transgene integration for advanced cell engineering and therapeutic development.
Electric Transfection employs precise electroporation technology to introduce genetic material directly into cells, enabling high-efficiency, non-viral gene delivery for CAR-T, CAR-NK, and other advanced cell engineering applications.
Transposon Transfection leverages transposon-based systems such as Sleeping Beauty and PiggyBac to achieve stable, integration-efficient, and cost-effective gene transfer, offering a versatile alternative to viral delivery for cell therapy development.
Q1: Which genome-editing systems are compatible with your service?
A1: Our platform accommodates multiple precision genome-editing technologies. Selection of the optimal tool is guided by experimental objectives, target cell characteristics, and desired genomic modifications. We recommend scheduling a technical consultation to tailor the strategy to your project.
Q2: Is your platform adaptable to custom cell lines?
A2: Our protocols are validated across a broad spectrum of cellular models, including standard laboratory lines and niche or primary cell types. Custom optimization ensures maximal editing efficiency and post-modification cell viability. Submit your cell line specifications for a feasibility assessment by our scientific team.
Q3: What measures are taken to maintain transgene expression fidelity post-integration?
A3: Stable expression is achieved through strategic selection of genomic loci with minimal epigenetic interference, deployment of high-activity promoters, and integration of anti-silencing genetic elements. Post-editing validation includes longitudinal expression profiling and epigenetic stability assessments to confirm durable functionality.
Q4: How are off-target events mitigated in your workflows?
A4: Computational guide RNA design, stringent nuclease activity optimization, and systematic off-target screening via NGS-based genome-wide analysis form the core of our risk-reduction strategy. Our pipelines prioritize on-target specificity while maintaining editing efficacy.
Q5: What distinguishes your methodology from conventional transfection approaches?
A5: Unlike traditional transfection, which yields stochastic integration and transient expression, our platform enables site-specific genomic integration with predictable, heritable expression kinetics. This precision enhances experimental reproducibility and eliminates artifacts associated with random insertional mutagenesis. Detailed comparative benchmarks are available upon request.
Creative Biolabs is a leading provider of innovative solutions for gene therapy and cell engineering. Our High-Efficiency Genomic Integration Service leverages cutting-edge technologies and extensive expertise to deliver exceptional results. Contact us today to discuss your project and learn how our service can help you achieve your research goals.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
